Literature DB >> 8354023

Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans.

R Zand1, S D Nelson, J T Slattery, K E Thummel, T F Kalhorn, S P Adams, J M Wright.   

Abstract

We studied the effect of isoniazid administration on the cytochrome P4502E1-catalyzed elimination of chlorzoxazone and acetaminophen. Isoniazid, 300 mg daily, was administered for 7 days to a group of 10 volunteer slow acetylators. Acetaminophen, 500 mg, and chlorzoxazone, 750 mg, were administered on separate occasions before isoniazid, during the period of isoniazid administration, and after the discontinuation of isoniazid. Isoniazid inhibited the clearance of chlorzoxazone by 58%, as assessed from plasma data, and inhibited the formation of acetaminophen thioether metabolites (a measure of the formation of the hepatotoxin N-acetyl-p-benzoquinone imine and catechol oxidative metabolites of acetaminophen, as determined from their recovery in urine, by 63% and 49%, respectively. Two days after the discontinuation of isoniazid, the clearance of chlorzoxazone was increased over the value before isoniazid by 56%. Acetaminophen thioether but not catechol metabolites were increased by 56% 1 day after the discontinuation of isoniazid and had returned to the pre-isoniazid value 3 days after the discontinuation of isoniazid. We conclude that the time course of the interaction with regard to chlorzoxazone elimination and formation is compatible with an inhibition-induction effect of isoniazid on cytochrome P4502E1. The mechanism of this biphasic effect is probably induction by protein stabilization, which results in inhibition of catalytic activity while isoniazid is present.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354023     DOI: 10.1038/clpt.1993.125

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

Review 1.  The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine.

Authors:  Hermann M Bolt; Peter H Roos; Ricarda Thier
Journal:  Int Arch Occup Environ Health       Date:  2003-03-01       Impact factor: 3.015

Review 2.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

3.  Spectrofluorimetric assessment of chlorzoxazone and ibuprofen in pharmaceutical formulations by using Eu-tetracycline HCl optical sensor doped in sol-gel matrix.

Authors:  M S Attia; M N Ramsis; L H Khalil; S G Hashem
Journal:  J Fluoresc       Date:  2011-11-09       Impact factor: 2.217

Review 4.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

5.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.

Authors:  Liudmila L Mazaleuskaya; Katrin Sangkuhl; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

6.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 7.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

9.  Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine in vivo.

Authors:  A M Jenner; J A Timbrell
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

Review 10.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.